Sternberg C N, Yagoda A, Casper E, Scoppetuolo M, Scher H I
Anticancer Res. 1985 Jul-Aug;5(4):415-7.
Elliptinium, 100 mg/m2 i.v. weekly, was administered to 14 patients with advanced renal cancer and 4 with breast cancer. There were no responses in 11 adequately treated patients. An unexpectedly high incidence of xerostomia, allergic, and hemolytic reactions were observed, which resulted in cessation of the trial. Recent data suggest polymer formation occurs with reconstituted elliptinium, and further trials are warranted when a new formulation is available.
以每周100mg/m²的剂量静脉注射椭圆玫瑰树碱，对14例晚期肾癌患者和4例乳腺癌患者进行治疗。11例接受充分治疗的患者均无反应。观察到口干燥症、过敏反应和溶血反应的发生率意外地高，这导致试验终止。最近的数据表明，重构的椭圆玫瑰树碱会形成聚合物，当有新的制剂可用时，有必要进行进一步试验。
